N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore
Why are we targeting the mid-domain of tau? This Alzforum story highlights preclinical data from our PRX005 program and discusses why targeting the middle region of tau may be the best way to block its aggregation and spread for the potential treatment of Alzheimer’s disease.